We are live on ! Find out more
ALT icon

Altimmune
ALT

143 hedge funds and large institutions have $389M invested in Altimmune in 2023 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

391% more capital invested

Capital invested by funds: $79.2M → $389M (+$310M)

124% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 25

71% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 24

66% more call options, than puts

Call options by funds: $32M | Put options by funds: $19.3M

28% more funds holding

Funds holding: 112 → 143 (+31)

6.79% more ownership

Funds ownership: 57.53% → 64.32% (+6.8%)

Holders
143
Holders Change
+31
Holders Change %
+27.68%
% of All Funds
2.08%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
56
Increased
41
Reduced
24
Closed
25
Calls
$32M
Puts
$19.3M
Net Calls
+$12.8M
Net Calls Change
+$11.5M

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$17.4M
2
Morgan Stanley
Morgan Stanley
New York
+$6.67M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.2M
4
TIM
Timelo Investment Management
Ontario, Canada
+$3.25M
5
Invesco
Invesco
Georgia
+$2.98M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$7.18M
2
Marshall Wace
Marshall Wace
United Kingdom
-$7.15M
3
APM
Avidity Partners Management
Texas
-$3.02M
4
AAP
Ardsley Advisory Partners
Connecticut
-$2.72M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nomura Holdings
151
Nomura Holdings
Japan
– -$710K -273,100 Closed
DFCM
152
Dark Forest Capital Management
Puerto Rico
– -$599K -230,353 Closed
XT
153
XTX Topco
Cayman Islands
– -$533K -204,998 Closed
Qube Research & Technologies (QRT)
154
Qube Research & Technologies (QRT)
United Kingdom
– -$465K -178,697 Closed
Citadel Advisors
155
Citadel Advisors
Florida
– -$499K -119,404 Closed
O
156
OrbiMed
New York
– -$260K -100,000 Closed
PIM
157
Platinum Investment Management
Australia
– -$247K -95,081 Closed
GCM
158
Graham Capital Management
Connecticut
– -$245K -94,105 Closed
AA
159
ALPS Advisors
Colorado
– -$101K -38,878 Closed
Connor, Clark & Lunn Investment Management (CC&L)
160
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$88.5K -34,052 Closed
DTL
161
Dynamic Technology Lab
Singapore
– -$78K -30,260 Closed
Mirae Asset Global Investments
162
Mirae Asset Global Investments
South Korea
– -$73.7K -28,352 Closed
EGM
163
Engineers Gate Manager
New York
– -$60.7K -23,355 Closed
QT
164
Quantbot Technologies
New York
– -$39.8K -15,300 Closed
PCM
165
Prelude Capital Management
New York
– -$32.8K -12,600 Closed
CC
166
Corton Capital
Ontario, Canada
– -$26.5K -10,202 Closed
CUAMC
167
China Universal Asset Management Company
China
– -$3.52K -1,354 Closed
3 4 5 6
7

ALT Hedge Fund Activity: Q4 2023 in Review

143 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2023, worth a combined $389M — up 391% from $79.2M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new ALT positions and 25 closed out — a net gain of 31 holders — while 41 added to existing stakes and 24 trimmed.

The largest buyer was Ameriprise, adding an estimated $17.4M. The largest seller was Nuveen, cutting an estimated $7.18M.

  • 143 institutional investors held Altimmune (ALT) as of Q4 2023, up from 112 in Q3 2023.
  • Funds reported $389M of Altimmune stock for Q4 2023, up 391% quarter-over-quarter.
  • 56 funds opened new Altimmune positions in Q4 2023 and 25 closed out, a net change of +31 holders.
  • The largest Altimmune buyer in Q4 2023 was Ameriprise, an estimated $17.4M added.
  • The largest Altimmune seller in Q4 2023 was Nuveen, an estimated $7.18M sold.

Based on aggregated 13F filings for Q4 2023.